Signal Diagnostics resolves uninsured-program overpayment allegations for $20.5 million
Oct 4, 2026 edition · GC-2026-0168 · Published 2026-10-04 · Version 2 · Settled
Signal Diagnostics agreed to pay $20.5 million over alleged retention of HRSA COVID-19 Uninsured Program payments for insured patients. DOJ describes conflicting insurance records and an internal audit that identified ineligible claims without the required refunds. Liability was not determined.
What happened
On September 30, DOJ announced that Signal Diagnostics agreed to pay $20.5 million to resolve False Claims Act allegations involving the federal COVID-19 Uninsured Program. The program reimbursed eligible providers for specified testing, treatment and vaccination services for uninsured individuals. Signal provided COVID-19 tests at public and client testing sites and submitted the disputed testing and specimen-collection claims between October 2020 and March 2022. The settlement addresses alleged avoidance of repayment obligations from January 2022 through May 2023, rather than a new coverage rule or a finding that all of Signal’s testing was improper.
DOJ says an internal audit beginning around January 2022 found claims for patients who had insurance. Alleged causes included multiple profiles for the same person with conflicting coverage information and claims submitted despite alternative insurance being listed in the system. Signal allegedly continued the audit, calculated overpayments and knowingly avoided refunding the ineligible amounts. That sequence distinguishes initial eligibility errors from what happens after a provider identifies an overpayment. The $20.5 million resolution settles those allegations; the release expressly states that there has been no determination of liability.
Scope and timing
- Authority status
- Settled
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
The action identifies a control failure relevant to provider, payer or vendor oversight. Its procedural status must be kept separate from any allegation.
Recommended action
Validate historical uninsured-program eligibility matching, later-discovered insurance, refund decisions and escalation documentation.
Case details
- agencies
- U.S. Department of Justice
- entities
- Signal Diagnostics LLC
- action Type
- Settlement
- event Date
- 2026-09-30
- alleged Conduct
- Alleged failure to refund uninsured-program payments for insured patients.
- resolution
- Civil settlement resolving allegations; no adjudication of liability is asserted.
Operational lessons
- Validate historical uninsured-program eligibility matching, later-discovered insurance, refund decisions and escalation documentation.
Sources
- Signal Diagnostics agrees to pay over $20 million to settle FCA allegationsOfficial · DOJ · 2026-09-30 · Source review 2026-10-04
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →